Nuvectis reports promising cancer treatment results

FORT LEE, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company valued at $144 million, announced today new research findings that show the potential benefits of their drug candidate, NXP900, in combination with osimertinib, in treating non-small cell lung cancer (NSCLC) with specific mutations. The company’s stock has recently experienced an 11% decline over the past week, though it maintains a positive 13% return year-to-date, according to InvestingPro data.

The study, conducted at the Lerner Research Institute of the Cleveland Clinic and published in Molecular Cancer Research, demonstrated that the combination therapy was more effective than osimertinib alone in both in vivo models and in vitro. The data suggests that adding NXP900 to osimertinib treatment could lead to decreased cancer cell proliferation and increased cell death. InvestingPro analysis shows the company maintains a healthy financial position with a current ratio of 2.09, indicating strong ability to fund ongoing research and development.

NXP900 is designed to inhibit the SRC Family of Kinases, which play a role in cancer cell growth and survival. The recent findings support the combination of NXP900 with EGFR inhibitors for tumors with EGFR mutations, building on previous research by AstraZeneca (NASDAQ:AZN) that showed NXP900 could reverse resistance to osimertinib in resistant cell lines.

Ron Bentsur, CEO of Nuvectis, expressed optimism about the potential of NXP900 for treating areas of unmet medical need, such as NSCLC. As the Phase 1a dose escalation study of NXP900 nears completion, the company is preparing to initiate the Phase 1b program.

The company’s other drug candidate, NXP800, is currently undergoing clinical trials for platinum-resistant ovarian carcinoma with ARID1a mutations and for cholangiocarcinoma.

While these findings are promising, they are forward-looking statements subject to risks and uncertainties, and the actual outcomes may differ. Nuvectis cautions that new risks may emerge over time, and it is not possible to predict all factors that could affect the success of their drug candidates. The information presented is based on a press release statement. Analysts maintain an optimistic outlook, with price targets ranging from $11 to $25 per share. For deeper insights into Nuvectis’s financial health and additional ProTips, visit InvestingPro, where subscribers can access comprehensive analysis and valuation metrics.

In other recent news, Nuvectis Pharma announced the initiation of an underwritten public offering of common stock. The company plans to sell all shares involved in this offering, with an additional 15% of shares available for purchase by underwriters within a 30-day period. The proceeds from this sale are intended to support the further development of Nuvectis’ drug candidates, NXP800 and NXP900, as well as for hiring, capital expenditures, and general corporate purposes. The offering’s completion and terms remain subject to market conditions, and there are no guarantees regarding its size or timing. Lucid (NASDAQ:LCID) Capital Markets is acting as the sole book runner for the transaction. The securities are being offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission earlier this year. Nuvectis is advancing NXP800 in Phase 1b trials and NXP900 in Phase 1a trials, targeting specific cancer mutations and kinases. These developments are based on a press release from Nuvectis Pharma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.